BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023
Retrieved on:
Thursday, May 11, 2023
Operating cost, International, BIOL, Tax, GAAP, Sale, Dentist, EBITDA, Investment, Depreciation, Growth, WETP, News, Video game, Bookkeeping
LAKE FOREST, Calif., May 11, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2023.
Key Points:
- Net revenue for the quarter ended March 31, 2023 was $10.5 million, an increase of 3% compared to net revenue of $10.2 million for the quarter ended March 31, 2022.
- U.S. laser revenue was $3.5 million for the quarter ended March 31, 2023, a decrease of 14% compared to U.S. laser revenue of $4.0 million for the quarter ended March 31, 2022.
- International laser revenue was $2.8 million for the quarter ended March 31, 2023, up 22% compared to $2.3 million for the quarter ended March 31, 2022.
- Gross margin for the quarter ended March 31, 2023 was 32% compared to 47% for the quarter ended March 31, 2022.